Organophosphate (OP) exposure can be lethal at high doses while lower doses may impair performance of critical tasks. The ability to predict such effects for realistic exposure scenarios would greatly improve OP risk assessment. To this end, a physiologically based model for diisopropylfluorophosphate (DFP) pharmacokinetics and acetylcholinesterase (AChE) inhibition was developed. DFP tissue/blood partition coefficients, rates of DFP hydrolysis by esterases, and DFP-esterase bimolecular inhibition rate constants were determined in rat tissue homogenates. Other model parameters were scaled for rats and mice using standard allometric relationships. These DFP-specific parameter values were used with the model to simulate pharmacokinetic data from mice and rats. Literature data were used for model validation. DFP concentrations in mouse plasma and brain, as well as AChE inhibition and AChE resynthesis data, were successfully simulated for a single iv injection. Effects of repeated, subcutaneous DFP dosing on AChE activity in rat plasma and brain were also well simulated except for an apparent decrease in basal AChE activity in the brain which persisted 35 days after the last dose. The psychologically based pharmacokinetic (PBPK) model parameter values specific for DFP in humans, for example, tissue/blood partition coefficients, enzymatic and nonenzymatic DFP hydrolysis rates, and bimolecular inhibition rate constants for target enzymes were scaled from rodent data or obtained from the literature. Good agreement was obtained between model predictions and human exposure data on the inhibition of red blood cell AChE and plasma butyrylcholinesterase after an intramuscular injection of 33 pg/kg DFP and at 24 hr after acute doses of DFP (10-54 pg/kg), as well as for repeated DFP exposures. The PBPK model for DFP was also adapted for the purpose of modeling parathion, including its metabolism to the toxic daughter product paraoxon. The development and validation of this PBPK model for two OPs provides a basis for studying the kinetics and in vivo metabolism of other bioactivated organophosphate pesticides and their pharmacodynamic effect in humans. -Environ Health Perspect 102(Suppl 11):51-60 (1994) 
Introduction
A variety of organophosphate (OP) esters inhibit acetylcholinesterase (AChE) in both central and peripheral nervous tissues resulting in excessive buildup of acetylcholine at neural receptors (1) . AChE accumulation causes a spectrum of acute toxic effects mediated by the nicotinic, muscarinic, and central nervous system interactions of acetylcholine. These range, depending on dose, from subclinical performance decrements to convulsions, asphyxia, and death (2) . A model capable of predicting the relationship between OP exposure and resultant toxic effects would be useful in risk assessment and the design of measures protective against exposure to cholinesterase inhibitors. Ideally, the model should be amenable to cross-species scaling and accurately predictive outside the dose range over which its primary validation studies were conducted. Physiologically based pharmacokinetic (PBPK) models meet these criteria (3) (4) (5) (6) (7) . They consist of descriptions of the physiology of the exposed organism and the biochemical processes, which are quantitatively important determinants of toxicant disposition. This includes parameters describing tissue solubilities, metabolism, and binding of the toxicant. A number of PBPK models have been developed for solvents and relatively stable halogenated compounds (5, 8, 9) . Additionally, an in vitro kinetic model for diisopropylfluorophosphate (DFP) in rat brain has been developed (10) , and a PBPK model for single dose pharmacodynamics of soman in rats was recently published (11) .
The goal of this study was to develop a quantitative, physiologically based model of OP pharmacokinetics and AChE inhibition. While AChE inhibition is not a toxic effect per se, it is an index of the probability that acute OP toxicity will occur (12) . DFP is not itself commercially important, but was chosen for this study as its mechanism of action is thought to be representative of other highly toxic OPs (12) . Parathion (PA) is an organophosphate insecticide that owes its toxicity to the oxidized product of parathion, paraoxon (PO). The metabolism of PA takes place predominantly in the liver, but it is also thought that some metabolism of parathion occurs in extrahepatic tissues. The basic model structure described herein for DFP and parathion should be applicable to other OPs whose acute toxicity is mediated by inhibition ofAChE.
Development of the Physiologically Based Pharmacokinetic Model
Elements ofModel Structure (Overview)
The major determinants of DFP disposition in vivo are its hydrolysis by esterases, binding to esterases, tissue solubility, and volatility (leading to exhalation). DFP is metabolized (hydrolyzed) by A esterases (AEST) to a noninhibitory product, diisopropylphosphoric acid (DIP). This organophosphate ester also binds to B esterases (BEST) and inhibits their enzymatic activity. The hydrolysis reaction is governed by Michaelis-Menten kinetics whose Vma. and K were determined with in vitro assays (Appendix 1). Those compartments described in the model as having A esterase activity (DFPase) are shown in Figure 1 as shaded areas. The binding to and inhibition of B esterases were modeled as bimolecular reactions and were also determined from in vitro studies (Tables 1 and 2). All tissue compartments in the model except fat were described as having B esterase activity (13) . The major determinants of parathion and paraoxon disposition in the model are metabolism of parathion to 
Hydrolysis ofParaoxon
The hydrolysis of paraoxon by A esterases was described with Michaelis-Menten kinetics, using data from Wallace and Dargan (16), Chemnitius et al. (17) , and Pla and Johnson (18) .
Diisopropylfluorophosphate Binding to Esterases
The schema for model simulations of free B esterase, in this case AChE, is shown in Figure 2 . (20) . Phosphorylated BESTs undergo spontaneous hydrolysis, leading to regeneration of the active enzyme ( Figure 2 ). For DFP, however, this process is relatively slow (21) ( Table 3) . Phosphorylated BEST may also undergo aging (22) , resulting in a permanent loss of activity ( Figure 2 ). BEST activities were obtained from Maxwell et al. (13) .
Basal activities of AChE, BChE, and CaE were defined by zero-order synthesis rates (moles bindinF sites/hour) and firstorder loss rates (hr ; Table 3 ). First-order loss of rat brain AChE was obtained from Wenthold (23) , who used radiolabled precursors of AChE to determine enzyme degradation. Synthesis of rat plasma and brain AChE was determined from model optimization of the data of Michalek (24) , Traina and Serpietri (25) . The zero-order synthesis rates and first-order loss rates for BESTs in rat plasma and in mice were estimated by fitting simulations to data describing the rate of return of enzyme activity to normal levels over time after DFP dosing (see "Results"). The synthesis and loss rates used for AChE were also used for BChE and CaE since the rate of increase of these activities after OP inhibition is close to that ofAChE (25, 26) .
Paraoxon Binding to Esterases
The activity of esterases which are inhibited by paraoxon were obtained from Maxwell (13) .
Metabolism ofParathion to Paraoxon
The metabolism of parathion to its toxic daughter product paraoxon was described in the model to occur in the liver and the kidney by Michaelis-Menten kinetics. The initial K and V for this metabolism m max were obtained from the work of Wallace and Dargan (16) . These rates of metabolism were optimized to provide better predictions of parathion and paraoxon pharmacokinetics.
Specification of Compartments
The PBPK model for DFP consisted of both organ-specific and lumped compartments ( Figure 1 ; Appendix 2; Table 4 ). (10) . bData from Vandekar and Heath (21) . CData from Andersen et al. (40) . dData from Martin (34) . "Data from Traina and Serpietri (25) . 'Data from Michalek et al. (24) . gData from Wenthold et al. (23) . The model tracked the inhibition of B esterases in brain, plasma, lung, diaphragm, kidney, liver, and slow and fast compartments. Data and model simulations are shown only for brain and plasma.
Organ-specific compartments were used to describe those tissues directly involved in acute DFP toxicity (e.g., brain, lung, diaphragm) or those expected to significantly influence DFP pharmacokinetics (e.g., blood, fat). Blood, though not a target organ, is an important site of DFP metabolism, and blood AChE is a useful reflection of AChE activity in less accessible organs. Separate venous and arterial compartments were used because it has been shown experimentally that there can be significant arterial-venous differences in DFP concentrations (27 
Partiton Coefficients
Partition coefficients for DFP (Table 5) were determined by the vial equilibration technique (31, 32) . DFP was injected into a closed vial containing heat-treated (60°C, 1 hr) rat blood or tissue homogenate at 37°C. After equilibration (2 hr), head space DFP space was quantitated by gas chromatography. Reference vials containing saline were treated identically. Tissue-blood partition coefficients were calculated by dividing the tissue-air value by that for blood-air. Partition coefficients determined for rat tissues were also used for simulations of mouse and human data. The muscle-blood partition was used for the lumped, slowly perfused compartment and the liver-blood partition for the lumped richly perfused compartment. The partitioning of parathion in the brain compartment was estimated from the data of Eigenberg et al. Parathion and paraoxon partitions in other tissues were determined in vitro by equilibrium dialysis (33) . A dominant characteristic of DFP pharmacokinetics well illustrated by this study is rapid clearance of free DFP from blood and brain. Free DFP in plasma had largely disappeared within 1 min of iv injection (Figure 3a) . In brain, free DFP at approximately 1 min post injection had fallen to a small fraction of its peak concentration (Figure 3b ). The PBPK model accurately simulated these data ( Figure  3a,b) . At time points greater than 5 min though, a less rapid disappearance of DFP from blood and brain than was predicted by the model was measured experimentally (Figure 3c,d) . However, the area under the plasma and brain concentration-time curves at these later time points represented less than 3% of the total free DFP dose to these tissues. It is possible that the apparent failure of the model to accurately track the free DFP concentration at later time points may be due to the measurement of 3H activity as a surrogate for the actual concentration of free DFP. Some 3H activity inferred to be free DFP may, in fact, have been a DFP metabolite or products of covalent binding.
Martin (34) also measured AChE inhibition in mice after iv injection of DFP. The nadir of AChE activity occurred within 1 min in plasma and at about 5 min in brain (Figures 4a,5a) . After optimization of AChE resynthesis, PBPK model simulations of these data were reasonably accurate from the time of injection through 24 hr (Figures 4b,5b ). The PBPK model was initially structured so that plasma and brain tissue AChE activities would return to 100% of control levels in about 3.75 days. Martin (34) found, however, that 7 days after a single iv injection of 1 mg DFP/kg, brain AChE activity in the mouse was only about 80% of the preexposure level (Figure 5c ). (25) measured the effect of DFP on plasma AChE activity using the same rat strain and dosing regimen as Michalek (24) . Traina and Serpietri (25) found that plasma AChE activity in the rat fell rapidly after sc injection of DFP (Figure 6a (Figure 7a,b) . The recovery of brain AChE activity after termination of DFP dosing was prolonged. For example, activity was only about 65% of control 28 days after the last dose of DFP. When the basal rates of AChE degradation and synthesis were optimized for acceptable simulation of brain AChE activity during dosing (Figure 7a ), simulation of AChE activity after termination of dosing predicted a more rapid return than was (Figure 8c ). During the first 5 days of repeated dosing, the actual AChE activity dropped rapidly from 100% of baseline to approximately 50% activity and then at a much slower rate to a final enzyme activity of 30%. The simulation of these data predicted a inhibition of approximately 40% during the initial 5 days of dosing that was sustained throughout the 480 600 rest of the exposure period. BChE activity dropped immediately during the first 5 days to 15% of the basal enzyme activity and se (AChE) in male remained at this level during the exposure propylfluorophos-period (Figure 8c ). The simulation pre-DFP/kg, then 0.7 dicted a 10 to 20% greater initial drop in Bra iareChErestied enzyme activity then was actually measured. r DFP dosing. Each Parathion and Paraoxon Kinetics in f six animals. Data the Rat depicts computer Eigenberg (37) measured concentrations of PA and PO in brain, liver, and blood, as well as PA in fat, following an iv injection of structure dic-PA at a dose of 3 mg/kg. Simulation of PA I monophasic and PO kinetics in brain, liver, and blood to the original after iv injection of 3.0 mg PA/kg were in ,est, however, general agreement with the published data hE activity to (Figures 9,10 ). The simulation of PA kinetsic process. also used for mice. This approach was also used for the DFP-esterase inhibition rate constants for CaE and BChE (see section on model development). The ability of the PBPK model to simulate AChE inhibition in mice and rats (Figures 4-7) indicates that the variance in these rate constants among tissues and species is not large. Andersen (40) found the rates of inhibition for solubilized AChE from the cerebral cortex of mice was within 20% of the rate for rats. 40 50 One goal of this research effort was to predict the kinetics and AChE inhibition not only after an acute exposure to DFP, but also after repeated doses. A good simulation of the experimental data for plasma and brain AChE inhibition in rats during repeated subcutaneous administration of DFP*was achieved (Figures 6,7) . The AMMA4W experimentally measured return of brain AChE activity was much slower than the rate of enzyme resynthesis that was used in the model. If the brain AChE resynthesis rate was decreased in the model to agree 40 50 with the rate of experimentally determined postexposure synthesis, then predictions of brain AChE activity during DFP dosing terase IChE) would be underestimated. ,nty-four hour
The experimentally determined activity from 10 to 54 of AChE in brain after each DFP dose was in 35 human human brain reproducible, yet the levels of AChE at the action of con-48-and 72-hr time points at the end of all repeated dosing indicated there was an alteration in the mechanisms controlling enzyme synthesis. For the model to predict the is a func-return of brain AChE to normal levels of nstant, ki. activity after repeated dosing, it would be ned in rat necessary to address the effects of down rege was then ulation of AChE receptors on AChE having this enzyme synthesis rates. The simulation of AChE was AChE resynthesis used the preexposed level ofAChE activity as a reference in setting the rate of resynthesis. This assumed that the 25 .0 30.0 Figure 9 . Simulated concentration of diisopropylfluorophosphate in human brain (mg/I) after a 5-min inhalation at 50 ppm. The level of plasma A esterates for curve A was 1.5 times the scaled activity; for curve B it was the scaled level of activity; and for C, it was 50% of the scaled activity. receptor affinity and impetus to return AChE to control tissue levels was unaltered. If the receptor numbers and affinities are affected by repeated dosing with DFP, it would alter the rates of AChE resynthesis experimentally, which would require a change in the model parameter controlling AChE synthesis. This effect is believed to be a response to excessive tissue concentrations of acetylcholine after AChE inhibition (41) . Clarification of the mechanism of this tolerance has involved the measurement of receptor binding and numbers. Binding of quinuclidinyl benzilate, a muscarinic affinity label, has been shown to decrease in affinity and density in the striatum of rats following chronic cholinesterase inhibition with DFP (42). Yamada (43) was able to demonstrate a correlation between and a dose-dependent decrease in muscarinic receptors, AChE activity, and choline uptake in regions of the brain and gastrointestinal tract of guinea pigs treated repeatedly with DFP. This effect was antagonized by physostigmine and atropine.
Simulations of the 24-hr recovery of brain AChE after repeated DFP dosing were well within one standard deviation of the data during the series of DFP doses and only failed to predict brain AChE levels after dosing had ceased. This could be due to the experimental protocol chosen by Michalek (24) , where 48 hr were allowed between each successive dose of DFP. Ehlert (42) has shown the half-time for the loss of muscarinic binding sites to be approximately 1.6 10 to 54 pg/kg. By using the data from human studies to validate the model, it is possible to simulate the amount of AChE inhibition in other target organs for which there are no human data ( Figure 12 ). This is significant, because it provides a means of predicting OP effects in the target organs of humans for which there will probably never be data. The development of this model to predict the human response to organophosphate exposure provides a method of modeling possible therapeutic or prophylactic approaches for organophosphate exposure in humans.
The model was exercised for a hypothetical inhalation exposure of humans to 50 ppm DFP for 5 min. Because CaE has been shown to be an important detoxification route for soman (20) , a simulation of human exposure to DFP was conducted with the activity of CaE decreased by a factor of 10, which is the activity expected in humans (44) . The effect of this alteration of CaE levels on the kinetics and inhibition of AChE was negligible due to the much lower affinity of CaE for DFP relative to the other enzymes present ( Table 1 ). The parameter that did have an effect on DFP blood and brain kinetics was AEST activity in the blood. The levels of AEST in blood were decreased by onehalf and increased by one-half over the amount that was scaled by (body weight) 0.7 from rats to humans. A 50% decrease in AEST activity in blood caused a 16% increase in the peak concentration of DFP in brain. In contrast, increasing DFP AEST activity by 50% caused an 9.5% decrease of DFP in blood and a 13% decrease in brain. Time (hours) 20 25 Figure (2) . The acute toxicities of some OP agents may not be due to acetylcholine overload but rather to actions at sites other than AChE (46) . In these cases, simulation of the concentration of free OP in target tissues would be expected to provide an index correlated with toxicity. For OPs whose primary mechanism of acute toxicity is not AChE inhibition, it would be desirable to extend the current PBPK model to explicitly describe the OP-tissue interaction most directly correlated with toxicity.
PBPK models are useful in risk assessment because their structure is amenable to cross-species scaling or to simulate exposure scenarios that cannot be tested otherwise. A PBPK model validated for experimental animals and appropriately scaled to humans is theoretically capable of simulating pharmacokinetic behavior in humans. This assumes that the model structure appropriate for the experimental species is also appropriate for humans. Physiological parameters such as organ volumes, organ blood flows, and pulmonary ventilation rates are well characterized for humans as well as for common experimental animals. Scaling of toxicant-specific parameters can be more problematical. Some success in scaling of PBPK models has been achieved by assuming that metabolic rates [e.g., Vmax, scale in proportion to body surface area (8) ]. With respect to the DFP model, it is not clear a priori how the DFP-esterase bimolecular inhibition rate constants should scale from rodents to humans. The ability demonstrated in rats and mice to successfully use in vitro estimates of parameter values for simulation of in vivo data suggested the same approach would work in the human version of the model. Moreover, the similarity of inhibition rates for solubilized AChE from the cerebral cortex of mice and rats (40) implies that some parameter values may be relatively insensitive to large changes in body weight.
In summary, the model structure used in the present study is clearly relevant to humans for a variety of OPs (2) and the data required for scaling is explicitly specified by this structure. Application of the present model to other OPs of concern for human exposure may, therefore, be a relatively straightforward task.
Appendix 1: Conversion of In Vitro Measurements for In Vivo Modeling
The two calculations shown here provide an example of the dimensional analysis to convert in vitro DFPase values of Vmax and Km for extrapolation to in vivo modeling. The values in Table 3 
